Collagen (XI) alpha-1 chain (COL11A1) is an independent prognostic factor in breast ductal carcinoma in situ by Toss, Michael S et al.
Collagen (XI) alpha-1 chain (COL11A1) is an independent prognostic 
factor in breast ductal carcinoma in situ 
Michael S Toss1,2, Islam M Miligy1,3, Kylie L Gorringe4,5, Mohammed A Aleskandarany1,3, 
Abdulbaqi Alkawaz1, Karuna Mittal6, Ritu Aneja6, Ian O Ellis1, Andrew R Green1 and Emad 
A Rakha1,3 
1Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School 
of Medicine, The University of Nottingham, Nottingham City Hospital, UK. 
2Histopathology department, South Egypt Cancer Institute, Assiut University, Egypt, 
3Histopathology department, Faculty of Medicine, Menoufia University, Egypt, 4Cancer 
Genomics Program, Peter MacCallum Cancer Centre, Melbourne, 5The Sir Peter 
MacCallum Department of Oncology, University of Melbourne, Parkville, Australia and 
6Georgia State University, Atlanta, GA, USA. 
  
Correspondence: 
Professor Emad Rakha 
Department of Histopathology, Nottingham University Hospital NHS Trust,  
City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK 
Tel: (44) 0115-9691169, Fax: (44) 0115-9627768 
Email: emad.rakha@nottingham.ac.uk, Emad.rakha@nuh.nhs.uk 
Key words: DCIS, COL11A1, stromal expression, recurrence, radiotherapy  
Running title: COL11A1 expression in DCIS   
Abstract 
 1
Collagen11A1 (COL11A1) is a fibrillary type collagen constituting a minor component of 
the extracellular matrix and plays role in tissue tensile strength. Overexpression of 
COL11A1 expression is associated with aggressive behavior and poor outcome in several 
human malignancies. In this study, we evaluated the association between COL11A1 
expression and clinicopathological parameters of the breast ductal carcinoma in situ 
(DCIS) and its prognostic value. COL11A1 protein expression was assessed 
immunohistochemically in a large well-characterized cohort of DCIS including pure 
(n=776) and DCIS associated with invasive carcinoma (DCIS-mixed, n=239). COL11A1 
expression was assessed in tumor cells and surrounding stromal cells and correlated with 
clinicopathological parameters, immunoprofile and disease outcome. In pure DCIS, high 
COL11A1 expression was observed in tumor cells and surrounding stromal cells in 25% 
and 13% of cases, respectively. Higher COL11A1 expression within the stromal cells was 
associated with hormone receptor negative, HER2 enriched and triple negative molecular 
subtypes and showed a positive linear correlation with proliferation index, dense tumor 
infiltrating lymphocytes and hypoxia-inducible factor 1 alpha. COL11A1 expression in 
tumor and stromal cells was significantly higher in DCIS associated with invasive 
carcinoma than in pure DCIS, and within the DCIS-mixed cohort, the invasive 
component showed higher COL11A1 expression than the DCIS component 
(all, p<0.0001). Overexpression of stromal COL11A1 was an independent predictor of 
s h o r t e r l o c a l r e c u r r e n c e f r e e i n t e r v a l f o r a l l r e c u r r e n c e s 
(HR=13.2, 95%CI=6.9-25.4, p<0.0001) and for invas ive recurrences 
(HR=11.2, 95%CI=4.9-25.8, p<0.0001). When incorporated with other risk factors, 
stromal COL11A1 provided better patient risk stratification. DCIS with higher stromal 
COL11A1 expression showed poor outcome even with adjuvant radiotherapy 
management.  
Conclusion: Overexpression of stromal COL11A1 is associated with invasive recurrence 
in DCIS and is a potential marker to predict the response to radiotherapy. 
INTRODUCTION 
Invasive breast carcinoma accounts for half of breast ductal carcinoma in situ (DCIS) 
recurrences (1-6). Several prognostic indices and molecular signatures have been 
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devised to assess the potential risk in DCIS towards its progression into invasive disease 
and to anticipate disease recurrence. However, the reliability and reproducibility of these 
indices are still insufficient for precise management decision making.  Lack of 
reproducibility and reliability of these signatures and indices might be a result of their 
focus on imprecise clinical parameters only such as Van Nuys Prognostic Index (4), or 
depending on molecular genetic signatures like Oncotype DX DCIS, which has been 
updated to incorporate other clinical data such patient age and DCIS size by the 
Genomic Health (www.genomichealth.com) (2). However, the latter mRNA-based 
signatures ignore the potential effect of post-transcriptional and post-translational 
modifications resulting in the differential expression of proteins within the tumor cells 
and subsequent effects of such changes on their functions. One more limitation of these 
assays is the collective measurement of gene expression levels in the tested tumor 
tissue sample, with variable proportions of tumor and stromal elements, therefore, 
omitting or underestimating the role of tumor microenvironment. Cancer is not 
exclusively a disease of tumor cells, but a disease of wider derangement and crosstalk 
involving tumor epithelial cells, surrounding stroma and tumor microenvironment 
including immune infiltrate. Recently, the role of microenvironment has been magnified 
in cancer development and progression and considered as a main component of cancer 
hallmarks (7). A supportive microenvironment could be crucial for remnant DCIS cells to 
survive therapy and develop invasive capabilities. Therefore, identification of more 
robust genetic and/or proteomic signatures incorporating the crosstalk between tumor 
epithelial cells and surrounding microenvironment might provide a better approach for 
DCIS risk assessment and hence better personalised management to avoid over- and 
under-treatment.  
Extracellular matrix and its main constituent, collagen, plays a critical role in several 
biological processes in normal tissues. Collagen is aberrantly produced by cancer 
associated fibroblasts, which reciprocally interact with tumor cells promoting the latter’s 
proliferation, migration and differentiation and, therefore, aiding cancer development 
and progression (8).   
Collagen11A1 (COL11A1) is a type of fibrillary collagen encoded by the COL11A1 gene 
and is expressed mainly in cartilaginous tissue (9). Its deficiency is associated with 
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skeletal and chondroid disorders (10, 11). It constitutes a minor component of the 
extracellular matrix and plays a role in its tensile strength. COL11A1 expression is 
associated with poor prognosis in non-small cell lung carcinoma and linked to its 
resistance to chemotherapy (12). Moreover, COL11A1 promotes malignant cell 
proliferation and is associated with worse prognosis in many other types of cancer 
including ovarian cancer, squamous cell carcinoma of the head and neck (13, 14), 
pancreatic (15), gastric (16), colorectal (17) carcinomas, and some sarcomas (18). It is 
also associated with metastasis in breast cancer (19) and was previously described as a 
diagnostic marker to differentiate between invasive and non-invasive breast cancer (20). 
COL11A1 predicts invasive recurrence after primary diagnosis of breast intraductal 
papillomas (21), and is differentially expressed between invasive breast carcinoma and 
DCIS (22). However, the role of COL11A1 in DCIS and its prognostic significance has yet 
to be investigated. In this study, we aimed to assess the pattern of COL11A1 expression 
and its association with DCIS behavior in large well-annotated DCIS cohorts composed of 
pure DCIS and DCIS associated with invasive disease.   
MATERIAL AND METHODS 
Study Cohort  
A large well characterized annotated cohort of DCIS including pure DCIS (n=776) and 
DCIS mixed with invasive breast carcinoma (DCIS-Mixed) (n=239) diagnosed between 
1990 to 2012 at Nottingham City Hospital, Nottingham, United Kingdom was used in this 
study, as previously described (23). To avoid selection bias, the DCIS-mixed cohort was 
selected with clinicopathological features comparable to the pure cohort regarding the 
range of age at diagnosis, DCIS nuclear grade, and presence of comedo type necrosis. 
All demographic, clinicopathological, management data, molecular subtype, tumor 
infiltrating lymphocytes density and hypoxia related markers in addition to local 
recurrence free interval data were available and prospectively maintained (24-26). 
Briefly, the molecular classes were defined based on the immunohistochemistry using 
estrogen and progesterone receptor, the human epidermal growth factor receptor 2 and 
Ki-67 proliferation index. Estrogen and progesterone receptor were considered positive if 
>1% of tumor cells showed nuclear staining (27) while the human epidermal growth 
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factor receptor 2 positivity was defined when more than 10% of tumor cells showed 
strong complete membranous staining (+3 score). Chromogenic in situ hybridisation 
technique was used to determine the gene amplification status in borderline cases (28). 
Proliferation index was defined as low when <14% of cells showed nuclear staining (29). 
In addition, hypoxia inducible factor 1 alpha was evaluated using immunohistochemistry 
and was considered positive when >1% of tumor cells showed nuclear staining as 
previously described (30) . Tumors with an average number of 20 lymphocytes/duct or 
more was considered as dense tumor infiltrating lymphocytes in DCIS as previously 
described (25).  Local recurrence free interval was defined as the time (in months) 
between 6 months after the primary DCIS excision and the development of ipsilateral 
recurrence (either as DCIS or invasive breast carcinoma). Cases undergoing completion 
re-excision due to margins’ involvement or presence of residual tumor tissue within the 
first 6 months were not considered as disease recurrence. Moreover, all cases with 
contralateral tumors or ipsilateral new event but developed in another quadrant, with 
morphological features different from the primary tumor or with nuclear downgrade were 
not considered as a recurrence and censored at time of the new event occurrence. In the 
pure DCIS cohort and within a median follow up period of 103 months (range 6-240), 83 
(11%) cases developed recurrence [30 cases (36%) recurred as DCIS and 53 (64%) 
recurred as invasive disease]. The majority of the recurrences (n=66) developed in 
patients treated with breast conserving surgery alone.  
Immunohistochemistry 
Tissue microarrays were prepared from both cohorts as previously described (23). 
Briefly, 1 mm punch sets were used to construct the tissue microarray using an 
automated Grand Master 2.4-UG-EN tissue microarray machine (3DHISTECH, Budapest, 
Hungary). For better representation of cases with heterogeneous DCIS histological 
patterns and/or nuclear grade, different areas representative of such heterogeneous 
patterns were sampled. Prior to immunohistochemical staining, full-face tissue sections 
from 10 randomly selected cases were stained and assessed to evaluate the pattern of 
COL11A1 expression in malignant breast tissue and adjacent stroma and normal 
terminal duct-lobular units. 
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Primary antibody specificity for anti-human COL11A1 mouse monoclonal antibody, clone 
1E8.33 [Ref#DMTX-0014, LOT#070912, Oncomatryx Biopharma S.L., Spain] was 
validated using Western blot on whole cell lysates of MCF7 and SKBR3 human breast 
cancer cell lines (obtained from the American Type Culture Collection; Rockville, MD, 
USA). COL11A1 antibody was used at a dilution of 1:1000, which showed a specific band 
at the predicted size of ~180 kDa.  
Expression of COL11A1 protein was assessed by immunohistochemistry using the 
Novocastra NovolinkTM Polymer Detection Systems kit (Code: RE7280-K, Leica, 
Biosystems, UK). Tissue microarrays and full-face sections (4 µm) were stained with 
mouse monoclonal COL11A1 (dilution 1:150), incubated for 24 hours after antigen 
retrieval using EDTA pH 9.0 in a water bath at 95oC. Hyaline cartilage tissue section in 
bronchi was used as positive control while the negative control was applied by omitting 
the primary antibody and both were simultaneously stained with the staining run.  
Scoring of COL11A1 expression  
Cytoplasmic expression of COL11A1 in tumor epithelial cells and the surrounding stromal 
cells was assessed. Semi-quantitative Histo-score was applied for cytoplasmic expression 
of COL11A1 in epithelial cells (staining intensity was multiplied by the percentage of 
representative cells in the tissue for each intensity, producing a range of values between 
0 and 300) (31). The percentage of stromal fibroblasts showing cytoplasmic staining was 
estimated, as the intensity of staining within the scanty cytoplasm of the slender 
fibroblasts was difficult to assess consistently. The tumor epithelial cells and surrounding 
fibroblasts were assessed and scored separately. Cores containing <15% of tumor 
epithelial cells and associated stroma were excluded from the scoring. All scored cores 
showed representative areas of specialized stroma (within two high power fields) (32) 
surrounding the malignant duct(s). In addition, a few cores with malignant epithelial 
cells without surrounding stroma were excluded. The cases excluded were unbiased. 
Cases with multiple cores were scored and the average final score was used for the 
analysis. Moreover, in the DCIS-mixed cohort, each component was evaluated and 
scored separately for the tumor epithelial cells and surrounding stroma. All cases were 
scored by two pathologists (MST and IMM) using a multiheaded microscope. For 
dichotomization of protein expression, outcome-dependent cut-off points for either 
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malignant epithelial cells or stromal expression of COL11A1 were defined according to X-
tile bioinformatics software (Yale University, version 3.6.1) (33) based on local 
recurrence free interval in the pure DCIS cohort. High COL11A1 expression within tumor 
epithelial cells was considered when Histo-score was >125, while expression in >15% of 
the surrounding fibroblasts was considered as high expression.  
Analysis of COL11A1 mRNA expression in breast cancer: 
To evaluate the prognostic role of COL11A1 in breast cancer and due to the scarcity of 
data on the genomic and proteomic profiles of DCIS, COL11A1 normalized mRNA 
expression was assessed as a potential predicative marker in the Molecular Taxonomy of 
Breast Cancer International Consortium cohort dataset (34), which comprises a large 
well characterised (n=1980) cohort of invasive breast cancer with representative 
molecular profile. Furthermore, to validate the prognostic role of COL11A1 in publicly-
available transcriptomic breast cancer data, analysis using the Breast Cancer Gene-
Expression Miner v4.1 (bc-GenExMiner v4.1) database was carried out. 
Statistical analysis 
Statistical analyses were performed using SPSS v21 (Chicago, IL, USA) for Windows. 
Student’s t-test and analysis of variance were used to correlate between COL11A1 mRNA 
level and other clinicopathological parameters in METABRIC data. Association with 
COL11A1 mRNA expression and breast cancer specific survival was performed after 
dichotomization of expression into high and low groups based on the median. 
Spearman’s Rho test was used to correlate between COL11A1 expression within the 
tumor and stromal cells; as well as their correlation with tumor infiltrating lymphocytes, 
Ki67, and the hypoxia inducible factor 1 alpha. Association between COL11A1 expression 
and clinicopathological parameters in pure DCIS was performed using Chi-square, Mann 
Whitney U and Kruskal-Wallis tests. Wilcoxon signed rank test was used to compare the 
expression of COL11A1 between DCIS component and invasive component within the 
DCIS-mixed cases. Univariate survival analysis against local recurrence free interval was 
carried out using log rank test and Kaplan Meier curves. Cox regression model was used 
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for multivariate analysis of COL11A1 expression for all recurrences (DCIS or invasive 
breast cancer) and invasive recurrences. For all tests, a two-tailed p-value of less than 
0.05 was considered as statistically significant. 
RESULTS 
The pattern of COL11A1 expression 
The evaluation of full-face tissue sections demonstrated even distribution of COL11A1 
expression in the tumor epithelial cells and the surrounding specialized stroma 
throughout the whole section, indicating representability of tissue microarrays to assess 
its expression. Adjacent normal breast terminal ducto-lobular units showed negative or 
faint cytoplasmic staining. When present, COL11A1 was expressed in the cytoplasm of 
the epithelial tumor cells and/or surrounding fibroblasts (Figure 1). Higher stromal 
COL11A1 expression was observed around DCIS with periductal stromal reaction.   
After unbiased exclusion of uninformative cores (lost, folded or those containing <15% 
tumor and surrounding stroma), the final number of cases suitable for scoring was 488 
pure DCIS and 184 DCIS-mixed. COL11A1 expression showed a unimodal distribution. 
The median Histo-score of protein expression within the tumor was 100 in pure DCIS 
(range 0-160), 110 in the DCIS component of mixed cases (range 0-170), and 140 in 
invasive component of the latter (range 0-200). For stromal expression, the median 
percentage of positive stromal cells was 0% in pure DCIS (range 0-50%), 20% in the 
DCIS component of mixed cases (range 0-80%) and 40% in the invasive component of 
the latter (range 0-100%). Within the pure DCIS cohort, high COL11A1 expression was 
observed in 25% and 13% in tumor epithelial cells and surrounding fibroblasts; 
respectively. There was a positive linear correlation between expression of COL11A1 
within the epithelial and surrounding stromal cells (Spearman’s correlation co-efficient 
r=0.3, p<0.0001).  
The proportion of cases with positive COL11A1 was significantly greater in DCIS-mixed 
than pure DCIS, both within the tumor cells (25% of pure DCIS cases vs. 40% of DCIS 
mixed with invasive breast cancer, χ2=14.9, p<0.0001) and stromal cells (13% for pure 
DCIS vs. 61% of DCIS mixed with invasion, χ2=26.3, p<0.0001). Similar results were 
observed when the data was analyzed using a continuous scale (p<0.0001 for both 
tumor epithelial cells and stromal cells). Moreover, there was a statistically significant 
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difference between COL11A1 expression within the tumor cells and surrounding stromal 
fibroblasts of the DCIS component and invasive component of DCIS-mixed cohort 
(p<0.0001 for both, using categorical and continuous data) (Figure 2).  
Significance of COL11A1 expression in pure DCIS 
High expression of COL11A1 within the malignant epithelial cells and/or surrounding 
stromal fibroblasts in the pure DCIS was associated with hormonal receptor negativity, 
HER2 enriched and triple negative molecular subtypes. No association was observed 
between COL11A1 expression and the conventional clinicopathological parameters used 
in DCIS risk assessment such as age at diagnosis, tumor size, DCIS nuclear grade, and 
comedo necrosis (Table 1). Analysis of continuous data of COL11A1 expression showed 
similar results (Supplementary Table 1). Moreover, there was a positive linear correlation 
between COL11A1 expression within tumor cells and surrounding fibroblasts with tumor 
proliferation fraction as assessed by Ki67 (r=0.3; p<0.0001, r=0.14; p=0.01, 
respectively), hypoxia inducible factor 1alpha (r=0.15; p=0.03, r=0.13; p=0.01, 
respectively) and tumor infiltrating lymphocytes density (r=0.15; p=0.009, r=0.2; 
p=0.001, respectively). 
To assess the prognostic value of COL11A1 in invasive breast cancer, the Molecular 
Taxonomy of Breast Cancer International Consortium cohort (34) was used to correlate 
the levels of COL11A1 mRNA expression with the clinicopathological variables and 
outcome. Higher COL11A1 mRNA level was associated with younger age (p<0.0001), 
lymph node metastasis (p=0.001), HER2 positivity (p<0.0001), HER2 enriched, triple 
negative and luminal B subtypes in addition to shorter breast cancer specific survival 
(HR=1.2, 95% CI=1.02-1.4, p=0.01) (Supplementary Tables 2, and Supplementary 
Figure 1).  Analysis using the Breast Cancer Gene-Expression Miner v4.1 (bc-GenExMiner 
v4.1) database showed that high COL11A1 mRNA was associated with significantly 
higher metastatic relapse and shorter overall survival (HR=1.1, 95% CI=1.02-1.3, 
p=0.03; Supplementary Figure 2).  
Outcome analysis in pure DCIS cohort  
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Higher COL11A1 expression within the epithelial tumor cells was associated with shorter 
local recurrence free interval for all recurrences (DCIS and invasive breast cancer) 
(HR=2.5; 95%CI=1.4-4.2, p=0.001) and showed a trend for invasive recurrences 
(HR=1.8; 95%CI=0.9-3.7, p=0.08) (Figure 3), while higher stromal expression was 
associated with shorter local recurrence free interval in the whole cohort for all 
recurrences and invasive recurrences (HR=15.9; 95%CI=9.1-27.5, p<0.0001 and 
(HR=12.1; 95%CI=6.1-24.0, p<0.0001, respectively) (Figure 4). Comparable results 
were obtained when the analysis was carried out with respect to different treatment 
groups (Figure 4). In the pure DCIS cohort, patients treated with breast conserving 
surgery and followed by adjuvant radiotherapy showed better outcome than those 
treated with breast conserving surgery only either for all recurrences (HR=0.5, 
95%CI=0.3-0.9, p=0.014) or invasive recurrence (HR=0.3, 95%CI=0.2-0.8, p=0.008) 
(Supplementary Figure 3). Interestingly, when the cohort was stratified according to 
COL11A1 expression, radiotherapy did not improve the outcome in patients with high 
stromal COL11A1 either in all recurrences (HR=0.8, 95% CI=0.5-1.6, p=0.587) or for 
invasive recurrences (HR=0.6; 95% CI=0.2-1.8, p=0.225) compared to patients with 
low COL11A1 expression (HR=0.2; 95% CI=0.2-0.9, p=0.04 for all recurrences and 
HR=0.4; 95% CI=0.1-0.7, p=0.03 for invasive recurrences) (Supplementary Figure 4). 
Support ing th is , eva luat ion o f the in teract ion between h igh s t romal 
COL11A1*radiotherapy using a Cox regression model showed significant association with 
shorter local recurrence free interval (HR=4.2, 95%CI=1.5-11.7, p=0.006). 
Furthermore, high COL11A1 expression within the stromal fibroblasts was associated 
with poorer outcome in all DCIS groups irrespective of the DCIS nuclear grade (low, 
intermediate and high) for all recurrences and for invasive recurrences (all p<0.0001). 
Supplementary Figure 5 shows forest plots for the univariate analysis of COL11A1 and 
other clinicopathological parameters and their association with outcome.      
Multivariate Cox proportional hazards analysis for the conventional clinicopathological 
parameters used to assess DCIS risk showed that patient’s age at diagnosis, DCIS size, 
nuclear grade, presence of comedo type necrosis and surgical resection margins were 
independent prognostic factors for disease recurrence. However, when expression of 
COL11A1 in stromal fibroblasts was included in the model, it was solely the independent 
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poor prognostic factor for tumor recurrence in patients treated with breast conserving 
surgery regardless of known other determinants of high risk DCIS; either for all 
recurrences (HR=13.2, 95%CI=6.9-25.4, p<0.0001) or when the analysis was confined 
to invasive recurrences (HR=11.2, 95%CI=4.9-25.8, p<0.0001), (Table 2). 
Interestingly, when COL11A1 expression in the surrounding fibroblasts was incorporated 
with the other determinants of DCIS risk described by Van Nuys Prognostic Index (35), it 
provided better stratification for local recurrence risk, whereby high expression of 
stromal COL11A1 was associated with poorer outcome in all risk groups when compared 
to similar groups with low COL11A1 expression (HR=1.9, 95% CI=1.2-3.1; p=0.004) 
(Supplementary Figure 6).  
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DISCUSSION 
Despite the advances in diagnostic and therapeutic modalities and the breakthrough in 
molecular genetics profiling, the underlying mechanisms promoting DCIS progression to 
invasive disease remain unclear and there is a desperate demand for better risk 
stratification tools. None of the currently available clinical indices or molecular signatures 
provide a reliable and clinically valid tool to predict DCIS risk of progression and/or 
recurrence to improve personalized management. Relying on the conventional methods 
for DCIS management by surgery with or without adjuvant radiotherapy for all patients 
based on such inadequate risk assessment leads to over- or under-treatment of a 
substantial proportion of patients. Furthermore, the biological and clinical heterogeneity 
of DCIS makes risk stratification quite challenging. Studying the role of DCIS 
microenvironment and the interaction between its various components and 
understanding how this affects disease behavior could resolve the DCIS dilemma and 
provide an adequate risk stratification model (36-39). As crosstalk between tumor 
epithelial cells and extracellular matrix including collagen remodelling, deposition and 
degradation is an essential key step in carcinogenesis and the progression of in situ 
tumors to invasive disease, studying potential markers that drive this process and their 
prognostic value is a credible approach to refine DCIS risk. 
COL11A1 is a minor fibrillary collagen present mainly in cartilage, but it is produced at 
varying levels by other normal tissues as well as and under some pathological 
conditions.  Interestingly, several studies reported that overexpression of COL11A1 by 
tumor cells and/or the surrounding cancer associated fibroblasts is linked with tumor 
progression and poorer prognosis in a variety of cancers including invasive breast cancer 
(12-14, 16, 17, 40). Moreover, in invasive breast cancer, some authors reported that 
COL11A1 is exclusively produced by invasive tumors (20), while others showed that it is 
expressed in normal, preinvasive and invasive tumors at different levels (40). COL11A1 
is differentially expressed between invasive breast cancer and DCIS (22), however there 
is no previous study investigating its role in DCIS progression and its potential 
prognostic significance. Furthermore, using the Molecular Taxonomy of Breast Cancer 
International Consortium cohort for robust molecular data in a large number of invasive 
breast cancer, we have shown an association between aggressive behavior of invasive 
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breast cancer and higher levels of COL11A1 mRNA. Taken together, these observations 
support our hypothesis that COL11A1 is a promising potential protein that could provide 
additional knowledge to DCIS behavior and might help in the stratification of disease 
risk.  
Here we explored the expression of COL11A1 in a large well characterized cohort of DCIS 
and scored the protein expression in tumor cells and surrounding stromal fibroblasts. 
Interestingly, high COL11A1 expression was associated with some features of high-risk 
DCIS, supporting its role in DCIS progression. Additionally, our data showed that 
COL11A1 expression was higher in DCIS co-existing with invasive breast cancer than 
pure DCIS, and much higher in the invasive component both within the tumor cells and 
in the surrounding stroma.    
The prognostic value of COL11A1 was shown with a shorter local recurrence free interval 
in patients with higher levels of COL11A1 expression, particularly stromal expression, 
independently from other clinicopathological factors. These findings were consistent for 
all recurrent events including DCIS and invasive breast cancer, and also when the 
analysis was confined to invasive recurrences only, which provides more evidence that 
COL11A1 could play a key role in DCIS progression to invasive disease. Although it was 
thought that COL11A1 is exclusively produced by cancer associated fibroblasts, other 
studies showed that COL11A1 was expressed in tumor cells as well as the surrounding 
stroma (22, 40). Our study showed that expression of COL11A1 in tumor epithelial and 
stromal cells is associated with disease recurrence; a finding that might reflect the 
epithelial-stromal interaction and its role in progression of DCIS. This interaction is 
supported by the obvious increase of COL11A1 expression in stromal and epithelial cells 
surrounding the invasive component compared to those surrounding the DCIS 
component in mixed cases or those surrounding pure DCIS. In our cohort, we have 
observed that higher expression COL11A1 is associated with periductal stromal reaction 
around DCIS, a finding that was reported to be associated with invasive recurrence in 
DCIS (41).  However, further functional studies are highly recommended to understand 
the underlying mechanisms and functions of COL11A1 expression in carcinogenesis and 
tumor progression either from the tumor cells or the surrounding stroma.       
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Multiple authors have noted a group of low grade DCIS with indolent appearance and low 
proliferation index that yet carries progression potential to invasive breast cancer 
(42-44). An explanation of disease progression based exclusively on intrinsic epithelial 
tumor cell-related factors is inadequate and identifying other candidate potential 
markers that could explain progression of different phenotypes and hence better risk 
stratification is highly warranted. Our findings showed that there was no association 
between high COL11A1 expression and other conventional clinicopathological factors that 
are described as a surrogate for high risk DCIS such as younger age at diagnosis, high 
grade DCIS, comedo type necrosis and mode of presentation. In addition, high 
expression of stromal COL11A1 showed an association with recurrence regardless the 
grade of the DCIS or method of therapy. These findings show that COL11A1 is a very 
promising protein for better DCIS risk stratification and understanding of the disease 
biology. Moreover, incorporation of COL11A1 with the other clinicopathological factors 
described in the Van Nuys Prognostic Index provided a better stratification of different 
risk groups. These findings indicate that COL11A1 is a marker that could be used to 
better define high-risk DCIS and identify of patients who need more radical treatment 
e.g. breast conserving surgery with wider excision margins or mastectomy. 
Although the effect of radiotherapy in reduction of DCIS recurrence in undeniable 
(45-48), there is still a considerable proportion of patients treated with breast conserving 
surgery and followed by adjuvant radiotherapy who develop disease recurrence. There 
are no data available for DCIS patients at higher susceptibility to show poor outcome 
after adjuvant radiotherapy management. Our findings showed that high expression of 
stromal COL11A1 is associated with higher rate of recurrence even with radiotherapy 
compared to DCIS with lower levels of expression, which indicates that COL11A1 could 
provide a signature for radiotherapy resistance in DCIS. However, the number of cases 
with recurrence after radiotherapy, especially invasive recurrence, is low, and this finding 
needs to be assessed in an independent cohort. Studies showed that dense stroma is 
associated with poor response to radiotherapy in cancer treatment (49, 50) which might 
provide a similar explanation in DCIS. These findings warrant more validation and 
mechanistic studies to decipher the underlying mechanisms and biology.    
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Our data support a key role for COL11A1 in progression to invasive disease and yet high 
levels of COL11A1 were highly significantly related to invasive recurrence. Thus far, 
understanding of the biological processes which involve COL11A1 in cancer progression 
is lacking, although we hypothesize that high stromal COL11A1 may in some way enable 
individual tumor cell invasion and/or remnant cell survival beyond the surgical margin, 
leading to invasive recurrence. Collagen provides a scaffold for the tumor cells and helps 
in tumor growth, angiogenesis and invasion (8). These findings are supported by the 
association between COL11A1 and proliferation and hypoxia related proteins in our 
cohort. The link between hypoxia and increased collagen deposition and remodelling 
through prolyl-hydroxylases and lysyl oxidase enzymes is well studied even in DCIS 
(51-53). One of the potential mechanisms that COL11A1 could use in promoting cellular 
proliferation is its association with the Smad signalling pathway via binding to integrin 
(12). In addition, it was thought that collagen acts as a barrier against tumor invasion, 
but now it is proven that it has multifaceted roles and could promote tumor progression. 
Increased collagen deposition promotes tumor progression through destabilization of cell 
polarity and cell-cell adhesion, and enhancement of growth factor signaling. Tissue 
tension regulates the epithelial-mesenchymal transition through crosslink between tumor 
cells and stromal cells (54, 55).  
Although the role of collagen in inflammatory processes and tissue healing is obvious, 
the specific role of COL11A1 in such conditions is unclear. Our data showed a correlation 
between higher COL11A1 expression mainly in stromal cells and dense inflammatory cell 
infiltrates. The underlying biology is warranted to be investigated, as we previously 
reported that dense tumor infiltrating lymphocytes have poor prognostic significance in 
DCIS, a phenomenon different from invasive disease and for which the underlying 
mechanisms are unclear (25). COL11A1 may interact with the inflammatory related 
markers; for instance, cytokines and or interleukins, and affect DCIS behavior.  
Conclusion  
Extracellular matrix remodelling is an essential feature associated with DCIS that could 
lead to either promoting or circumventing its progression to invasive disease. COL11A1 
might have a potential role in DCIS aggressiveness through its collagen remodeling and 
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regulatory mechanism in cellular proliferation. Additional functional studies to decipher 
the role of COL11A1 and its mechanism of action in DCIS behavior are indicated. 
Applying COL11A1 in clinical practice, especially stromal expression, would provide a 
highly promising prognostic indicator for DCIS invasive recurrence and may be a 
potential predictive marker for radiotherapy response. As a consequence, the group of 
patients with high stromal COL11A1 (13% of cases) could require more extensive 
surgery, regardless of other factors.  
Limitations of the study 
This study has been carried out on tissue microarray sections, which might 
underestimate the role of tumor heterogeneity. However, all cases in our cohort were 
histologically reviewed before tissue microarray construction and we used multiple cores 
for cases with heterogeneous grades or morphological patterns. Moreover, our cohort did 
not include any patients treated with endocrine therapy, and the number of recurrences 
after radiotherapy was small. Further validation studies on larger cohorts especially with 
radiotherapy treated patients is highly warranted.  
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Table 1: Correlation between COL11A1 expression with different clinicopathological 
parameters in the pure DCIS cohort. 
Significant p values are in bold  
COL11A1; Collagen (XI) alpha-1 chain, DCIS; ductal carcinoma in situ, HER2; Human epidermal 
growth factor receptor 2, HIF1α; hypoxia-inducible factor 1 alpha. 
Clinicopathological  
Parameters
COL11A1 
expression in 
tumor epithelial 
cells χ2 
(p-
value)
COL11A1 
expression in 
stromal fibroblasts
χ2 
(p-
value)Low 
(N=338) 
N. (%)
High 
(N=110
) 
N. (%)
Low  
(N=391) 
N. (%)
High 
(N=57) 
N. (%)
Age (years) 
   ≤50  
   >50 
81 (24) 
257 (76)
27 (25) 
83 (75)
0.1 
(0.902) 91 (23) 300 (77)
17 (30) 
40 (70)
1.2 
(0.280)
Presentation  
   Screening 
   Symptomatic
166 (49) 
172 (51)
52 (47) 
58 (53)
0.1 
(0.737)
193 (49) 
198 (51)
25 (44) 
32 (56)
0.6 
(0.438)
DCIS Size (mm) 
   ≤20 
   >20
147 (44) 
191 (56)
51 (47) 
57 (53)
0.4 
(0.497)
163 (43) 
223 (57)
30 (54) 
25 (46)
2.6 
(0.106)
Nuclear Grade 
   Low 
   Moderate 
   High
40 (12) 
88 (26) 
210 (62)
13 (12) 
31 (28) 
66 (60)
0.2 
(0.903)
49 (13) 
102 (26) 
240 (61)
4 (7) 
17 (30) 
36 (63)
1.6 
(0.457)
Comedo necrosis  
   Yes 
   No
221 (65) 
117 (35)
76 (69) 
34 (31)
0.5 
(0.475)
258 (66) 
133 (34) 
39 (68) 
18 (32)
0.1 
(0.716)
Estrogen receptor   
   Negative 
   Positive
77 (25) 
233 (75)
34 (33) 
69 (67)
2.6 
(0.105)
87 (24) 
272 (76)
24 (44) 
30 (56)
9.8 
(0.002)
Progesterone receptor 
   Negative 
   Positive
119 (38) 
192 (62)
53 (52) 
48 (48)
6.3 
(0.012)
144 (40) 
217 (60)
28 (55) 
23 (45)
4.1 
(0.042)
HER2 status  
   Negative 
   Positive
231 (76) 
74 (24)
75 (74) 
27 (26)
0.2 
(0.655)
289 (77) 
85 (23)
39 (70) 
17 (30)
1.5 
(0.211)
Proliferation index (Ki-67) 
   High 
   Low
62 (23) 
210 (77)
25 (24) 
78 (76)
0.1 
(0.762)
70 (22) 
255 (78)
17 (34) 
33 (66)
3.8 
(0.049)
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative
139 (54) 
47 (18) 
40 (15) 
34 (13)
47 (48) 
18 (18) 
17 (17) 
17 (17)
1.5 
(0.685)
167 (54) 
57 (18) 
43 (14) 
42 (14)
19 (38) 
8 (16) 
14 (28) 
9 (18)
8.2 
(0.041)
T u m o r i n f i l t r a t i n g 
lymphocytes  
   Dense 
   Sparse 
122 (47) 
137 (53)
49 (57) 
37 (43)
2.5 
(0.113)
140 (47) 
158 (53)
31 (66) 
16 (34)
5.9 
(0.016)
HIF1A expression 
   High 
   Low
58 (24) 
188 (76)
26 (29) 
63 (71) 1.1 (0.293)
63 (21) 
228 (78)
21 (48) 
23 (52)
13.8 
(<0.000
1)
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Table 2: Multivariate survival analysis (Cox regression model) of variables (with and 
without COL11A1) predicting outcome in terms of ipsilateral local all recurrences (A) and 
invasive recurrences (B) in patients treated by breast conserving surgery in pure DCIS. 
A) All recurrences  
Significant p values are in bold  
COL11A1; Collagen (XI) alpha-1 chain, DCIS; ductal carcinoma in situ. 
Conventional clinicopathological parameters associated with high risk DCIS  
Parameters  Hazard 
ratio (HR)
95% confidence interval 
(CI)
  
p-value
Lower Upper
Patient Age 0.4 0.2 0.8 0.006
DCIS presentation 1.5 0.9 2.4 0.111
DCIS size 1.5 1.1 2.1 0.040
DCIS nuclear Grade 1.9 1.3 2.7 0.001
Comedo necrosis 0.6 0.4 0.9 0.049
Margin status 0.8 0.7 0.9 0.004
COL11A1 and other clinicopathological parameters associated with high risk 
DCIS
High stromal COL11A1 expression 13.2 6.9 25.4 <0.0001
Patient Age 0.6 0.3 1.4 0.261
DCIS presentation 1.9 0.9 3.9 0.084
DCIS size 1.1 0.7 1.9 0.609
DCIS nuclear Grade 1.6 0.9 3.1 0.123
Comedo necrosis 0.5 0.2 1.2 0.120
Margin status 1.0 0.9 1.1 0.728
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B) Invasive recurrence  
      Significant p values are in bold  
COL11A1; Collagen (XI) alpha-1 chain, DCIS; ductal carcinoma in situ. 
Conventional clinicopathological parameters associated with high risk DCIS  
Parameters  Hazard 
ratio (HR)
95% confidence interval 
(CI)
  
p-value
Lower Upper
Patient Age 0.5 0.2 1.3 0.156
DCIS presentation 1.4 0.8 2.6 0.245
DCIS size 1.8 1.1 2.4 0.013
DCIS nuclear Grade 1.9 1.1 3.0 0.013
Comedo necrosis 0.7 0.4 1.3 0.274
Margin status 0.9 0.8 1.1 0.075
COL11A1 and other clinicopathological parameters associated with high risk 
DCIS
High stromal COL11A1 expression 11.2 4.9 25.8 <0.0001
Patient Age 0.9 0.3 3.3 0.974
DCIS presentation 2.0 0.8 5.2 0.156
DCIS size 1.5 0.7 2.9 0.258
DCIS nuclear Grade 1.9 0.8 4.4 0.119
Comedo necrosis 0.5 0.2 1.3 0.159
Margin status 1.1 0.9 1.2 0.386
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Supplementary Table 1: Correlation between COL11A1 expression and different 
clinicopathological parameters in the pure DCIS cohort using continuous data. 
  
Significant p values are in bold  
COL11A1; Collagen (XI) alpha-1 chain, DCIS; ductal carcinoma in situ, HER2; Human epidermal 
growth factor receptor 2, HIF1α; hypoxia inducible factor 1 alpha. 
Supplementary Table 2: Correlation between COL11A1 mRNA level and the 
clinicopathological parameters in the METABRIC series of invasive breast cancers 
(n=1980). 
Clinicopathological  
Parameters
Number 
of cases
COL11A1 expression 
in tumor epithelial 
cells 
COL11A1 expression 
in stromal 
fibroblasts
Mean 
Rank p-value
Mean 
Rank p-value
Age (years) 
   ≤50  
   >50 
108 
340
225.8 
224.1
0.904 233.4 
221.7
0.296
Presentation  
   Screening 
   Symptomatic
218 
230
222.8 
226.1
0.789 219.5 
229.2 0.312
DCIS Size (mm) 
      ≤20  
      >20
198 
248
223.2 
223.7
0.965 232.4 
216.3
0.094
Nuclear Grade 
   Low 
   Moderate 
   High
53 
119 
276
223.1 
224.0 
225.0
0.993
201.6 
214.8 
233.1
0.056
Comedo necrosis  
   Yes 
   No
297 
151
215.6 
229.1
0.295 226.7 
220.2
0.523
Estrogen receptor   
   Negative 
   Positive
111 
302
244.7 
193.15
<0.0001 236.9 
196.0
<0.0001
Progesterone Receptor 
   Negative 
   Positive
172 
240
233.8 
186.9
<0.0001 222.2 
195.3
0.004
HER2 status 
   Negative 
   Positive
306 
101
198.0 
222.1
0.073 210.6 
231.4
0.061
Proliferation index (Ki-67) 
   High 
   Low
87 
288
215.6 
179.6
0.006 203.6 
183.6
0.055
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative
186 
65 
57 
51
166.4 
179.1 
215.8 
190.7
0.014
167.9 
177.4 
212.7 
190.9
0.004
T u m o r i n f i l t r a t i n g 
lymphocytes    
   Dense 
   Sparse
171 
174
189.1 
157.1 0.003
187.1 
159.1 0.001
HIF1A expression  
   High 
   Low
84 
251
192.2 
159.9
0.008 192.3 
159.8
0.001
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Significant p values are in bold  
METABRIC; Molecular Taxonomy of Breast Cancer International Consortium 
C l i n i c o p a t h o l o g i c a l 
parameters
Number of 
cases
Mean COL11A1 mRNA 
level
p-value
Patient Age (years) 
   <50  
   ≥50 
383 
1556
8.7 
8.8
<0.0001
Tumor Size (mm) 
   ≤20 
   >20
622 
1331
8.7 
8.7
0.803
Histologic Grade 
   1 
   2  
   3
170 
770 
952
8.8 
8.9 
8.9
0.621
Lymph node Stage  
   1 
   2 
   3
1035 
622 
316
8.7 
8.9 
8.8
0.001
Estrogen Receptor Status 
   Positive 
   Negative
1506 
474
8.7 
8.7
0.163
HER2 Status 
   Negative 
   Positive
1733 
247
8.7 
8.8
<0.0001
PAM50 molecular classes 
   Luminal A 
   Luminal B 
   Basal-like 
   HER2 enriched 
   Normal like
718 
488 
329 
240 
199
8.7 
8.9 
8.9 
8.7 
8.5
<0.0001
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Figures:  
Figure 1: Representative photomicrographs of COL11A1 IHC expression, A) Normal breast 
ductolobular unit (x20) shows negative staining of COL11A1 in epithelial cells and occasional staining in 
the surrounding fibroblasts; B) Negative COL11A1 expression (x20) in a pure DCIS case; C) strong 
expression of COL11A1 in tumor cells and surrounding fibroblasts (x20) in a pure DCIS case; D and E) 
Expression of COL11A1 in a mixed case (x40) showing strong staining in invasive component within 
the tumor cells and/or surrounding stromal fibroblasts; and F) negative expression of COL11A1 in a 
mixed case (x20). 
!
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Figure 2: Violin plots showing differences of COL11A1 expression between pure DCIS and DCIS-mixed 
both in tumor cells (A) and surrounding stroma (B).   
  
&
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Figure 3: Kaplan Meier curves showing that high expression of COL11A1 within the tumor epithelial 
cells is associated with ipsilateral local recurrence free interval in the whole series either for all 
recurrences (A) or invasive recurrences (B), in breast conserving surgery without adjuvant 
!
!
!
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radiotherapy (C; all recurrences and D; invasive recurrences) and in patients treated with breast 
conserving surgery followed by adjuvant radiotherapy (E; all recurrences and F; invasive recurrences).  
 30
Figure 4: Kaplan Meier curves showing that high expression of COL11A1 within the surrounding 
stromal fibroblast is associated with ipsilateral local recurrence free interval in the whole series either 
for all recurrences (A) or invasive recurrences (B), in breast conserving surgery without adjuvant 
!
!
!
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radiotherapy (C; all recurrences and D; invasive recurrences) and in patients treated with breast 
conserving surgery followed by adjuvant radiotherapy (E; all recurrences and F; invasive recurrences).  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Supplementary Figures:  
&  
Supplementary Figure 1: Association between COL11A1 mRNA level and outcome in terms of breast 
cancer specific survival in the METABRIC series. The cohort was split into high and low mRNA 
expression at the median mRNA expression.  
 33
Supplementary Figure 2: Association between COL11A1 mRNA level and outcome (Metastasis free 
survival) in Breast Cancer Gene-Expression Miner database.  
&
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Supplementary Figure 3: Kaplan Meier curves showing the association between radiotherapy and 
better outcome in the pure DCIS cohort for all recurrences (A) and invasive recurrences (B).   
&
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Supplementary Figure 4: Kaplan Meier curves showing that radiotherapy is associated with better 
outcome in patients treated with breast conserving surgery and have low stromal COL11A1 expression 
for all recurrences (A), and invasive recurrences (C). While patients with high stromal expression of 
COL11A1 showed no difference in recurrence rate after radiotherapy for all recurrences (B), and for 
invasive recurrences (D).   
&
!
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Supplementary Figure 5: Forest plots showing the univariate analysis results of association between 
different clinicopathological parameters and ipsilateral tumor recurrence for patients treated with 
breast conserving surgery in pure DCIS cohort; A) all recurrences whether DCIS or invasive and B) for 
invasive recurrences only. 
!
!
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Supplementary Figure 6: Kaplan Meier curves showing the association between DCIS risk and local 
recurrence free interval in patients treated with breast conserving surgery based on Van Nuys 
Prognostic Index alone (A), and when COL11A1 was incorporated with the Van Nuys Prognostic Index 
(B).
!
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